Literature DB >> 18083

Azlocillin: in vitro studies of a new semisynthetic penicillin.

D Stewart, G P Bodey.   

Abstract

The activity of azlocillin, a new semisynthetic penicillin, was determined against 582 clinical isolates of gram-negative bacilli and gram-positive cocci. Over 75% of the isolates of Pseudomonas aeruginosa were inhibited at a concentration of 12.5 mug or less per ml. Azlocillin is also active against indole-negative and -positive Proteus spp., inhibiting 98 and 71%, respectively, at a concentration of 12.5 mug or less per ml. Isolates of Klebsiella spp. and Enterobacter spp. showed less susceptibility than isolates of Escherichia coli and Serratia spp. Gram-positive cocci except penicillin G-resistant Staphylococcus aureus were susceptible to azlocillin. Azlocillin failed to inhibit the growth of gram-negative bacilli when large inocula were used. It was more active in alkaline pH, but the type of medium used had little effect on its activity. Azlocillin was more active than mezlocillin, ticarcillin, and carbenicillin and as active as BLP-1654 against isolates of P. aeruginosa. It was not as active as mezlocillin against the majority of the other gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18083      PMCID: PMC352088          DOI: 10.1128/AAC.11.5.865

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Proceedings: Causes of death in cancer patients.

Authors:  J Inagaki; V Rodriguez; G P Bodey
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

2.  Infectious complications in renal transplant recipients.

Authors:  T C Eickhoff
Journal:  Transplant Proc       Date:  1973-09       Impact factor: 1.066

3.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

5.  Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity.

Authors:  G P Bodey; V Rodriguez; S Weaver
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

6.  In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins.

Authors:  G P Bodey; D Stewart
Journal:  Appl Microbiol       Date:  1971-04
  6 in total
  27 in total

1.  Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.

Authors:  R D Lander; R P Henderson; D R Pyszczynski
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

3.  Pharmacokinetics of Bay k 4999, a new broad-spectrum penicillin.

Authors:  R Wise; B Cadge; A P Gillett; A Bhamjee; R Livingston; P G Welling; D P Thornhill
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

4.  High-pressure liquid chromatographic quantitation of azlocillin.

Authors:  A Weber; K E Opheim; K Wong; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

5.  Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

7.  In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.

Authors:  J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

8.  The pharmacokinetics of furazlocillin in healthy humans.

Authors:  P H Hinderling; U Gundert-Remy; D Förster; W Gau
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

9.  Comparative in vitro study of temocillin (BRL 17421), a new penicillin.

Authors:  R Bolivar; S S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

10.  [Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].

Authors:  Z Modr; K Dvorácek; I Janků; V Krebs
Journal:  Infection       Date:  1982       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.